Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.48 |
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.46 |
| ▸ | TTR known ✓ | P02766 | 2/20 | 0.42 |
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.41 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.41 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.41 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.41 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.41 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.41 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.41 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 0.41 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.41 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 1/20 | 0.41 |
| ▸ | GABRG3 known ✓ | Q99928 | 1/20 | 0.41 |
| ▸ | GABRQ known ✓ | Q9UN88 | 1/20 | 0.41 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2810739 | 1.00 | KDM4E (0.54) | KDM4EMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL109155 | 0.97 | KDM4E (0.56) | KDM4EMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL1478628 | 0.94 | KDM4E (0.54) | KDM4EMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL2888306 | 0.94 | KDM4E (0.54) | KDM4EMEN1KMT2AALDH1A1LMNA | |
| Ammonia Solution, Strong SCHEMBL9859476 | 0.94 | KDM4E (0.54) | KDM4EMEN1KMT2AALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL9311860 | 0.94 | KDM4E (0.54) | KDM4EMEN1KMT2AALDH1A1LMNA | |
| Water SCHEMBL2806532 | 0.94 | KDM4E (0.54) | KDM4EMEN1KMT2AALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL8653192 | 0.94 | KDM4E (0.54) | KDM4EMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL1477467 | 0.94 | KDM4E (0.54) | KDM4EMEN1KMT2AALDH1A1LMNA | |
| Ethylene SCHEMBL29067611 | 0.92 | KDM4E (0.52) | KDM4EMEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2000065-A | — | — | None | — | — | JP | disclosed |
| CN-119955767-A | In vitro reconstitution of the calvin cycle system | 中国科学院遗传与发育生物学研究所 | 2025-05-09 | — | — | CN | disclosed |
| EP-4549472-A2 | COMPOSITIONS FOR SUNSCREEN COMPOUNDS AND METHODS THEREOF | PMIDG, LLC (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-4013374-B1 | COMPOSITIONS FOR SUNSCREEN COMPOUNDS AND METHODS THEREOF | PMIDG LLC (US) | 2025-02-19 | — | — | EP | disclosed |
| CN-118948676-A | Compositions for sunscreen compounds and methods thereof | 普米戴格有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118593387-A | Compositions for sunscreen compounds and methods thereof | 普米戴格有限公司 | 2024-09-06 | — | — | CN | disclosed |
| US-11873389-B2 | Composition and molded article | AKITA UNIVERSITY (JP) | 2024-01-16 | — | — | US | disclosed |
| CN-113195625-B | Composition and molded article | 国立大学法人秋田大学 | 2023-05-02 | — | — | CN | disclosed |
| US-20220296485-A1 | COMPOSITIONS FOR SUNSCREEN COMPOUNDS AND METHODS THEREOF | PMIDG, LLC | 2022-09-22 | — | — | US | disclosed |
| EP-4013374-A1 | COMPOSITIONS FOR SUNSCREEN COMPOUNDS AND METHODS THEREOF | PMIDG, LLC (US) | 2022-06-22 | — | — | EP | disclosed |
| US-5672696-A | HEATING DEPARAFFINIZED TISSUE SAMPLE IN PROTEIN-DENATURING AQUEOUS SUSPENSION CONTAINING SURFACTANT, THEN TREATING SUSPENSION WITH PROTEASE AND MIXING WITH SOLUTION OF HYDROXYBENZOIC ACID | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1997-09-30 | — | — | US | disclosed |
| WO-1997008145-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-03-06 | — | — | WO | disclosed |
| US-5602277-A | Substituted benzene derivatives useful as neuraminidase inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 1997-02-11 | — | — | US | disclosed |
| WO-1996030329-A1 | SUBSTITUTED BENZENE DERIVATIVES USEFUL AS NEURAMINIDASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INCORPORATED (US) | 1996-10-03 | — | — | WO | disclosed |
| US-5514676-A | TO INHIBIT THE FORMATION OF ADVANCED GLYCOSLYATION PRODUCTS BY THE NONENZYMATIC CROSSLINKING OF PROTEINS WITH REDUCING SUGARS, USED IN FOOD PRESERVATION AND TO PREVENT PROTEIN AGING IN COLLAGEN OR LENSES IN THE EYE PRESERVATION | THE ROCKEFELLER UNIVERSITY (US) | 1996-05-07 | — | — | US | disclosed |
| EP-0692533-A1 | Treatment of paraffin embedded tissue for gene analysis | WAKO PURE CHEMICAL INDUSTRIES LTD (JP) | 1996-01-17 | — | — | EP | disclosed |
| EP-0368474-B1 | Enhanced amperometric sensor | MEDISENSE INC (US) | 1995-12-13 | — | — | EP | disclosed |
| US-5264106-A | Enhanced amperometric sensor | MEDISENSE, INC. (US) | 1993-11-23 | — | — | US | disclosed |
| EP-0368474-A2 | Enhanced amperometric sensor | MediSense, Inc. (US) | 1990-05-16 | — | — | EP | disclosed |
| JP-H0265-A | PRODUCTION OF PHOTOSENSITIVE RESIN CAPABLE OF DEVELOPING WITH WATER-BASED SOLVENT | TOKYO METROPOLIS | 1990-01-05 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296485-A1 | COMPOSITIONS FOR SUNSCREEN COMPOUNDS AND METHODS THEREOF | NQO1, XPA, ERCC1 | CA2 4032/4885DPP4 4166/4885TTR 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.